Is Enclomiphene FDA Approved? A Look at Its Status

Enclomiphene is not FDA approved. Despite multiple clinical trials and at least one formal FDA review dating back to 2007, the drug has never received regulatory approval in the United States for any indication. The compound was developed under the brand name Androxal by Repros Therapeutics for the treatment of secondary hypogonadism in men, but the FDA did not find the evidence sufficient to grant approval. Today, enclomiphene circulates widely through compounding pharmacies and online telehealth clinics, which has created a confusing situation where many people use a drug they assume has been vetted by regulators when it has not.

Why the FDA Said No

The regulatory story of enclomiphene stretches back nearly two decades. Repros Therapeutics submitted enclomiphene citrate (Androxal) for FDA review for the treatment of secondary male hypogonadism. The FDA did not consider increases in testosterone levels alone to be sufficient evidence for approving a non-testosterone therapy for hypogonadism. The agency also rejected normalization of luteinizing hormone (LH) and improvements in quality of life as adequate endpoints for approval.¹

This rejection reflected a broader FDA position that was emerging at the time: showing a drug raises a hormone number on a lab test is not the same as showing it produces meaningful clinical benefit. For testosterone therapies in general, the agency has increasingly asked companies to demonstrate improvements in things patients actually feel, such as sexual function, energy, or physical performance, rather than just a bump in serum testosterone. Enclomiphene’s developer was unable to clear that bar to the agency’s satisfaction, and by 2016 the program had effectively stalled. Repros Therapeutics was later acquired, and no new FDA application for enclomiphene has been filed since.

How Enclomiphene Differs from Clomiphene

To understand why enclomiphene attracts so much interest, it helps to know where it comes from. Clomiphene citrate, marketed as Clomid, has been used for decades to induce ovulation in women and is sometimes prescribed off-label for men with low testosterone. Clomiphene is actually a mixture of two geometric isomers: enclomiphene (the trans isomer) and zuclomiphene (the cis isomer). These two molecules have different biological behaviors.²

In animal studies, enclomiphene acts primarily as an estrogen receptor antagonist, meaning it blocks estrogen’s effects. Zuclomiphene, by contrast, has more estrogenic (estrogen-like) activity. Early research in immature rats found that both isomers could stimulate uterine growth, but enclomiphene required a substantially lower dose to reach half-maximal effect compared to zuclomiphene, suggesting it is the more pharmacologically active of the pair at the estrogen receptor.³ The thinking behind isolating enclomiphene as a standalone drug was straightforward: strip out the zuclomiphene isomer, which was suspected of causing many of clomiphene’s side effects, and you might get a cleaner, better-tolerated medication.

The Mechanism in Men

Enclomiphene works by occupying estrogen receptors in the hypothalamus, the part of the brain that monitors hormone levels. Normally, when testosterone gets converted to estrogen in the body, that estrogen signals the hypothalamus to dial down production of LH and follicle-stimulating hormone (FSH). Those two hormones are what tell the testes to make testosterone and sperm. By blocking estrogen from reaching the hypothalamus, enclomiphene tricks the brain into thinking estrogen levels are low, which causes LH and FSH to rise, which in turn drives the testes to produce more testosterone.¹

This is fundamentally different from testosterone replacement therapy (TRT), which introduces testosterone from outside the body. Exogenous testosterone shuts down the brain’s signaling to the testes, which is why men on TRT typically see their LH, FSH, and sperm counts drop, sometimes dramatically. Enclomiphene does the opposite: it keeps the body’s own production machinery running, which is why fertility preservation has been one of its main selling points.

What the Clinical Trials Actually Showed

Several phase II and phase III trials tested enclomiphene in men with secondary hypogonadism, and the hormone numbers were generally encouraging. In one pharmacokinetic study, men taking 25 mg of enclomiphene daily reached mean testosterone levels around 604 ng/dL after six weeks. Men on transdermal testosterone gel reached about 500 ng/dL, with more variability between individuals. Both groups saw testosterone rise, but they had opposite effects on LH: enclomiphene raised it while testosterone gel suppressed it.⁴

A randomized phase II trial comparing enclomiphene to topical testosterone found that enclomiphene raised morning testosterone, estradiol, and LH levels similarly to the gel, while also preserving sperm counts. FSH and LH both increased in the enclomiphene group, confirming that the hypothalamic-pituitary-gonadal axis stayed active.⁵ A 16-week study in obese hypogonadal men showed the same pattern: testosterone went up in all treatment groups, but FSH and LH only increased in the enclomiphene arms, while they decreased in the testosterone gel group.⁶

So the drug clearly does what its proponents claim on the hormone level. The gap that the FDA identified was between “raises testosterone on a blood test” and “produces clinical outcomes that matter to patients.” Whether enclomiphene reliably improves sexual function, energy, mood, or body composition in a way that justifies approval as a standalone medication remains, from a regulatory perspective, unproven. One review of selective estrogen receptor modulators (the broader drug class enclomiphene belongs to) noted that these agents produced only a small improvement in body composition.⁷

The Side Effect Advantage over Clomiphene

One area where enclomiphene’s data looks particularly strong is tolerability. A study comparing adverse effects in men taking clomiphene versus enclomiphene found a stark difference. Roughly 47% of men on clomiphene reported side effects, compared to about 14% on enclomiphene. Decreased libido hit about a third of clomiphene users but under 9% of enclomiphene users. Reduced energy affected about 17% on clomiphene versus 5% on enclomiphene. And mood changes showed up in about 9% of the clomiphene group but were absent entirely in the enclomiphene group.⁸

These differences make biological sense. Zuclomiphene, the isomer present in regular clomiphene but absent in enclomiphene, has more estrogenic activity. In men, unwanted estrogenic stimulation can cause mood disruption, low libido, and fatigue, exactly the side effects that dropped when zuclomiphene was removed from the equation. This is probably the strongest practical argument for enclomiphene over generic clomiphene: similar testosterone-boosting results with a fraction of the side effects that make men quit clomiphene.

How People Get It Without FDA Approval

Despite lacking approval, enclomiphene is not hard to find. Compounding pharmacies can legally produce enclomiphene because the raw chemical is not a controlled substance. These pharmacies buy pharmaceutical-grade enclomiphene citrate powder from chemical suppliers and compound it into capsules. A number of men’s health telehealth platforms have built their business models around prescribing compounded enclomiphene, sometimes marketing it as a fertility-friendly alternative to TRT.

There are real concerns with this arrangement. Compounded drugs are not subject to the same manufacturing standards, quality testing, or batch consistency requirements as FDA-approved medications. The FDA has periodically warned about the risks of compounded drugs in general, including contamination, incorrect dosing, and lack of sterility where applicable. For enclomiphene specifically, there is no FDA-approved reference product, which means compounding pharmacies are working from published literature and prescriber judgment rather than a standardized, agency-reviewed formulation. You are trusting the compounding pharmacy’s quality control process and the prescribing clinician’s familiarity with the evidence.

The doses most commonly used in clinical practice tend to be in the range of 12.5 to 25 mg daily, drawn from what the clinical trials tested. But without a standardized label, there is variation in how clinicians prescribe it and how pharmacies formulate it. If you are considering enclomiphene, asking your pharmacy about their testing and verification procedures is reasonable due diligence.

Bone Density and Long-Term Safety Gaps

One of the bigger unknowns with enclomiphene is what happens over longer time horizons. Most of the published clinical data covers treatment periods of 6 to 16 weeks, which is long enough to observe hormone changes but too short to assess outcomes like bone health, cardiovascular risk, or metabolic effects. A phase III trial was designed to evaluate the effects of 12 months of Androxal treatment on bone mineral density in men with secondary hypogonadism, including DEXA scanning and lean soft tissue assessment.⁹ However, because the drug program stalled, the results from longer-term safety studies are limited in the public literature.

This is not a trivial gap. Testosterone plays an important role in maintaining bone density in men, and one of the concerns about hypogonadism is the elevated fracture risk that comes with it. Showing that enclomiphene raises testosterone on a lab slip does not automatically mean bones get stronger, because the downstream effects depend on how consistently testosterone stays elevated, how the body responds at the tissue level, and whether estrogen signaling (which enclomiphene partially blocks) also plays a protective role in male bone metabolism. Estrogen actually matters for male bones more than most people realize, and blocking its receptor activity in a chronic, systemic way could theoretically work against bone health even while testosterone numbers look good. This is speculative, but it is exactly the kind of question that FDA-mandated long-term safety data would have answered.

The Anti-Doping Angle

Because enclomiphene substantially boosts endogenous testosterone, it has attracted attention from the World Anti-Doping Agency (WADA). Clomiphene, which includes enclomiphene as one of its isomers, is listed under Section 4.2 of the WADA Prohibited List and is banned at all times, both in and out of competition. Detection windows for clomiphene and its metabolites can be prolonged after someone stops taking the drug. WADA has even issued specific guidance noting that clomiphene metabolites can appear in human urine after consuming eggs or meat from poultry treated with the compound.¹⁰

For competitive athletes subject to drug testing, this means enclomiphene is firmly off-limits regardless of whether a doctor prescribes it for a legitimate medical reason. A Therapeutic Use Exemption (TUE) would be required, and those are difficult to obtain for substances that directly raise testosterone. The long detection window also means that stopping enclomiphene weeks before a competition may not be enough to clear a drug test. Anyone competing in a WADA-governed sport should be aware that enclomiphene will trigger a positive result for a prohibited substance.

Enclomiphene Versus Off-Label Clomiphene for Men

In practice, the comparison most men face is not between enclomiphene and TRT but between enclomiphene and generic clomiphene, which is cheap, widely available, and commonly prescribed off-label by urologists and endocrinologists for male hypogonadism. Generic clomiphene contains both isomers, and many men do well on it. The case for switching to enclomiphene rests almost entirely on tolerability: if you are one of the men who experiences mood swings, low libido, or visual disturbances on clomiphene, enclomiphene may deliver the testosterone benefit without those problems.

The cost difference is meaningful. Generic clomiphene costs a few dollars per month through a standard pharmacy with insurance or a GoodRx-type discount. Compounded enclomiphene typically runs considerably more, sometimes $50 to $150 or more per month depending on the pharmacy and whether you are going through a telehealth service that bundles consultations and lab work into a subscription fee. Whether that premium is worth it depends on how much trouble you are having with generic clomiphene’s side effects.

There is also the question of zuclomiphene accumulation. Zuclomiphene has a longer half-life than enclomiphene and can build up in the body with chronic use. Some clinicians believe this accumulation explains why side effects from clomiphene tend to worsen over time in some men. With pure enclomiphene, that accumulation does not happen, which may make it a better choice for long-term use. The evidence for this is more theoretical than proven in controlled trials, but it aligns with what is known about the two isomers’ pharmacology.

What “Not FDA Approved” Actually Means for You

The lack of FDA approval does not automatically mean enclomiphene is unsafe or ineffective. Plenty of drugs are used off-label with strong supporting evidence, and the clinical data on enclomiphene’s ability to raise testosterone while preserving fertility is fairly consistent. What the non-approval does mean is that several layers of consumer protection are missing. There is no standardized dose. There is no FDA-reviewed label listing contraindications, drug interactions, and warnings based on a complete review of all trial data. There are no post-marketing surveillance requirements that would catch rare adverse events. And there is no manufacturing standard specific to enclomiphene, since each compounding pharmacy operates under its own processes.

If you are using or considering enclomiphene, the practical takeaway is to treat it with the same seriousness you would treat any prescription medication. Get baseline bloodwork and follow up regularly. Work with a clinician who understands the evidence, not just a telehealth provider running through a checklist. Ask your compounding pharmacy about their purity testing. And be honest with yourself about what the drug can and cannot do: it will likely raise your testosterone numbers, but whether that translates into the energy, libido, or body composition changes you are hoping for is less certain than the lab results might suggest.

The Poultry Problem in Drug Testing

One genuinely surprising wrinkle in the enclomiphene and clomiphene story involves agriculture. Clomiphene is sometimes used in poultry farming to boost egg production, and its metabolites can end up in the meat and eggs of treated birds. WADA has acknowledged this as a potential source of inadvertent positive drug tests and has responded by setting a minimum reporting level for clomiphene in urine samples.¹⁰ The levels from dietary exposure are far below what you would see from therapeutic use, but they can still register on sensitive assays. For non-athletes this is a curiosity; for anyone subject to workplace drug panels that happen to screen for anti-estrogens, it is worth knowing that the compound has a surprisingly broad environmental footprint.